Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
April 20, 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA...
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
March 29, 2023 08:00 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 22, 2023 07:30 ET
|
Wave Life Sciences USA, Inc.
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended...
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
March 02, 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
February 09, 2023 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
December 19, 2022 07:37 ET
|
Wave Life Sciences USA, Inc.
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compared with Wave’s first-generation...
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
December 13, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and...
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in...
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
November 09, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
November 03, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...